BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38535990)

  • 1. RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma.
    Lu D; Mihoayi M; Ablikim Y; Arikin A
    Aging (Albany NY); 2024 Mar; 16(7):5929-5948. PubMed ID: 38535990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
    Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cells.
    Yu X; Zheng B; Chai R
    Biosci Rep; 2014 Dec; 34(6):e00161. PubMed ID: 25370813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
    Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
    BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiles of immune cell infiltration in head and neck squamous carcinoma.
    Liang B; Tao Y; Wang T
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
    Liu J; Deng W; Xiao Z; Huang X; Lin M; Long Z
    J Immunol Res; 2022; 2022():8976179. PubMed ID: 36157883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi-Mediated Silencing of EIF3D Alleviates Proliferation and Migration of Glioma U251 and U87MG Cells.
    Ren M; Zhou C; Liang H; Wang X; Xu L
    Chem Biol Drug Des; 2015 Oct; 86(4):715-22. PubMed ID: 25682860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of HOX genes promotes cell migration and proliferation in head and neck squamous cell carcinoma.
    Aguiar GM; Ramão A; Plaça JR; Simões SC; Scaraboto NV; Freitas-Castro F; Cardoso C; Sousa JF; Silva WA
    Tumour Biol; 2021; 43(1):263-278. PubMed ID: 34633333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
    Xing L; Zhang X; Tong D
    DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Shi Y; Huang J; Hu Y; Shen Y
    BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
    Chen Y
    Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
    Huang C; Liu J
    Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of eukaryotic translation initiation factor 3 subunit D (eIF3D) inhibits proliferation of acute myeloid leukemia cells.
    Liu GZ; Liu JZ; Li XQ; Zhang L; Li SJ; Xiao TW; Wang JX; Li GY; Liu Y
    Mol Cell Biochem; 2018 Jan; 438(1-2):191-198. PubMed ID: 28801778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
    Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
    Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
    World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.